Top in hem/onc: Blood test for cancer, glioblastoma treatment

A novel blood-based assay demonstrated the ability to detect five cancer types up to 4 years earlier than current screening methods, according to a recent study. It was the top story in hematology/oncology last week.

Another top story was about the orphan drug designation of rhenium nanoliposomes (Plus Therapeutics) for the treatment of recurrent glioblastoma.

Read these and more top stories in hematology/oncology below:

Blood test detects common cancer types 4 years before current screening methods

The noninvasive PanSeer test (Singlera Genomics), which is based on DNA methylation, detected stomach, esophageal, colorectal, lung and liver cancer in 91% of asymptomatic individuals who were diagnosed with cancer 1 to 4 years later using standard detection methods. Read more.

FDA grants orphan drug designation to novel glioblastoma treatment

The FDA recently granted orphan drug designation to rhenium nanoliposomes for patients with recurrent glioblastoma. The treatment is designed to safely deliver a dose of radiation directly into the brain tumor that is 25 times greater than what is delivered using external beam radiation therapy. Read more.

Grassroots group of physicians rallies broad support for masking, universal mandate

Since the start of the COVID-19 pandemic, Vineet Arora, MD, MAPP, MHM, knows that medical professionals have been diligent about universal masking in hospitals as a preventive measure. Read more.

FDA approves Onureg for AML in first remission

The FDA has approved a new once-daily oral therapy for the treatment of certain patients with acute myeloid leukemia. Read more.

Discussion on cancer screening, continuation of treatment crucial during COVID-19 pandemic

In this article, experts discuss the problem of delayed cancer screenings and treatments during the COVID-19 pandemic. Read more.